Fig. 5: A431 SCC tumour growth and metastasis are abolished by the opposite targeting of p110δ and RhoA.

a A431 cells were stably transfected with different p190RhoGAP shRNAs. The proliferation rate in clones (C8 and C10) with the highest silencing efficacy was determined and compared with that of control A431 cells. The symbols on the different groups denote data from three different experiments performed in triplicate. b NSG mice were inoculated with A431 cells on day 0 and treated with intravenous injections of WT macrophages or intravenous injections of WT macrophages and intratumoural injections of p190RhoGAP siRNA or intravenous injections of δ^D910A/D910A macrophages and intratumoural injections of p190RhoGAP siRNA on day +10 and on every other day until the end of the experiment. Tumour growth was measured. n = 9 mice/group. Each symbol on the different groups denotes data from a different animal of the respective group. c Intravasation efficiency of A431 cells as determined by tumour cells blood burden at the end point of the experiments in NSG mice (n = 9 mice/group) which received WT or δ^D910A/D910A macrophages (starting on day +10) and intratumoural injections of p190RhoGAP siRNA. Each symbol on the different groups denotes data from a different animal of the respective group. All graphs represent means ± s.e.m. Statistically significant differences are indicated by *** (P < 0.001), as determined by the one-way ANOVA and the Mann-Whitney U test.